Researchers led by Dr. Alexandros Karakostis from the Institute for Archaeological Science and the Senckenberg Center for ...
Following the first 1000 days of life that span from conception to two years of age, the next 1000 days of a child's life from 2–5 years of age offer a window of opportunity to promote nurturing and ...
EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...
A local research and development business is looking for people to take part in a study focused on addressing age-related ...
The Huntington's disease (HD) mutation eventually causes a fatal brain disease in adulthood, but a new study finds that early in life, children with the HD mutation have bigger brains and higher IQ ...
Building upon decades of professional expertise and research, CogniTherapeutics empowers parents in fostering their child's ...
offering a new approach to early detection and intervention. Neurodevelopmental disorders like autism spectrum disorder (ASD) and ADHD affect millions worldwide, influencing brain development and ...
Could social bonds be the key to human big brains? A study of the fossil teeth of early Homo from Georgia dating back 1.77 million years reveals a prolonged childhood despite a small brain and an ...
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...